Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real‐World Observational Study ( <scp>FOSAPO</scp> )
Switching from CSAI to CSFLI is feasible, effective, and well tolerated. Behavioral changes observed in two cases underline the need for clinical awareness when treating patients with subtle cognitive vulnerability.
Authors
- Clément Desjardins (ORCID: https://orcid.org/0000-0003-1569-9590)
- Quentin Salardaine (ORCID: https://orcid.org/0000-0002-5513-9865)
- Guillaume Baille
- Jean‐Philippe Brandel
Institutions
- Fondation de Rothschild (FR)
Publication Details
- Journal
- Movement Disorders Clinical Practice
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1002/mdc3.70254
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39